1. Home
  2. CRSP vs GSHD Comparison

CRSP vs GSHD Comparison

Compare CRSP & GSHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • GSHD
  • Stock Information
  • Founded
  • CRSP 2013
  • GSHD 2003
  • Country
  • CRSP Switzerland
  • GSHD United States
  • Employees
  • CRSP N/A
  • GSHD N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • GSHD Specialty Insurers
  • Sector
  • CRSP Health Care
  • GSHD Finance
  • Exchange
  • CRSP Nasdaq
  • GSHD Nasdaq
  • Market Cap
  • CRSP 3.3B
  • GSHD 2.9B
  • IPO Year
  • CRSP 2016
  • GSHD 2018
  • Fundamental
  • Price
  • CRSP $36.29
  • GSHD $108.26
  • Analyst Decision
  • CRSP Buy
  • GSHD Buy
  • Analyst Count
  • CRSP 16
  • GSHD 10
  • Target Price
  • CRSP $73.07
  • GSHD $115.40
  • AVG Volume (30 Days)
  • CRSP 2.1M
  • GSHD 277.4K
  • Earning Date
  • CRSP 05-06-2025
  • GSHD 07-23-2025
  • Dividend Yield
  • CRSP N/A
  • GSHD 5.46%
  • EPS Growth
  • CRSP N/A
  • GSHD 129.07
  • EPS
  • CRSP N/A
  • GSHD 1.26
  • Revenue
  • CRSP $37,675,000.00
  • GSHD $324,757,000.00
  • Revenue This Year
  • CRSP $26.79
  • GSHD $18.40
  • Revenue Next Year
  • CRSP $297.32
  • GSHD $24.82
  • P/E Ratio
  • CRSP N/A
  • GSHD $85.98
  • Revenue Growth
  • CRSP N/A
  • GSHD 21.87
  • 52 Week Low
  • CRSP $30.04
  • GSHD $54.80
  • 52 Week High
  • CRSP $67.88
  • GSHD $130.39
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 46.12
  • GSHD 52.04
  • Support Level
  • CRSP $35.38
  • GSHD $104.53
  • Resistance Level
  • CRSP $38.13
  • GSHD $110.83
  • Average True Range (ATR)
  • CRSP 1.73
  • GSHD 3.27
  • MACD
  • CRSP -0.03
  • GSHD 0.36
  • Stochastic Oscillator
  • CRSP 26.30
  • GSHD 50.68

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About GSHD Goosehead Insurance Inc.

Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions.

Share on Social Networks: